Researchers from Rowan University, Pennsylvania State University, and affiliated organizations presented preclinical data for the selective Mcl-1 inhibitor, KS-18, in models of multiple myeloma (MM).
Insitro Inc. has signed three strategic agreements with Eli Lilly & Co. focused on advancing potential new medicines for metabolic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), based on targets identified by Insitro using its artificial intelligence/machine learning-based platform.
The identification of non-toxic targets for the treatment of metabolic disorders would allow the development of therapies for the harmful effects of impaired metabolism of reactive aldehydes, among others, which is challenging for drug development due to short half-life and lack of tissue specificity.
Researchers from Rhodes University and collaborators identified MMV-1645152 after screening the Medicines for Malaria Venture (MMV) pandemic response box for non-cytotoxic inhibitors of Kaposi's sarcoma-associated herpesvirus (KSHV) replication.
Axonal regrowth is a crucial process for forming a compensatory neuronal network after spinal cord injury (SCI), but this is very limited in the adult mammalian central nervous system.
Ono Pharmaceutical Co. Ltd. has entered into a license agreement with Ligachem Biosciences Inc. for LCB-97, a preclinical stage antibody-drug conjugate (ADC) for solid tumors.
Clinical research has shown that patients with systemic lupus erythematosus (SLE) are more likely to develop cardiovascular disease (CVD), including cardiac and vascular dysfunction. In the current study, researchers from Medical University of South Carolina developed and characterized a novel preclinical model of SLE-like CVD.
RSS
